ClinicalTrials.gg
Active, not recruitingNCT05052996Updated Feb 4, 2026Results posted

Study Evaluating the Safety and Efficacy of Islatravir in Combination With Lenacapavir in Virologically Suppressed People With HIV

A Phase 2 interventional study of ISL and LEN in HIV-1 Infection, sponsored by Gilead Sciences. Active, not recruiting at 44 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-04.

Sponsored by Gilead Sciences · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
142
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The primary objective of this study is to evaluate the efficacy of oral weekly islatravir (ISL) in combination with lenacapavir (LEN) in virologically suppressed people with HIV (PWH) at Week 24.

02

Conditions studied

  • HIV-1 Infection
03

In context

Lead sponsor

Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.

Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Received bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) for ≥ 24 weeks at screening.
  • Documented plasma type 1 (HIV-1) ribonucleic acid (RNA) \< 50 copies/mL (or undetectable HIV-1 RNA level according to the local assay being used if the limit of detection is ≥ 50 copies/mL) for ≥ 24 weeks before and at screening.
  • Plasma HIV-1 RNA \< 50 copies/mL at screening.

Key Exclusion Criteria:

  • History of prior virologic failure while receiving treatment for HIV-1.
  • Prior use of, or exposure to, islatravir (ISL) or lenacapavir (LEN).
  • Active, serious infections requiring parenteral therapy \< 30 days before randomization.
  • Active or occult virus (HBV) coinfection, defined as hepatitis B core antibody (HBcAb) positive, hepatitis B surface antigen (HBsAg) positive, or HBV deoxyribonucleic acid (DNA) positive as determined by the central laboratory.
  • Active virus (HCV) coinfection, defined as detectable HCV RNA.
  • Any of the following laboratory values at screening:

    • (CLcr) ≤ 30 mL/min according to the Cockcroft-Gault formula
  • CD4+ T-cells \< 200 cells/mm\^3 (Cohort 1); CD4+ T-cells \< 350 cells/mm\^3 (cohort 2).
  • Absolute lymphocyte count \< 900 cells/mm\^3 (cohort 2).
  • Individuals of (as defined in protocol) who have a positive serum pregnancy test at screening or positive urine and serum pregnancy tests at Day 1 prior to study drug administration.
  • Individuals who plan to continue breastfeeding during the study.
  • Documented historical or screening resistance reports showing nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) or non-nucleoside/nucleotide reverse transcriptase inhibitors (NNRTIs) resistance mutations in reverse transcriptase, including M184V/I (Cohort 2).

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
142 participants (actual)

Study arms

  • Experimental
    Cohort 1 (ISL+LEN)

    Participants will receive the following for at least 48 weeks: * Day 1 and Day 2: ISL 40 and LEN 600 mg * Day 8 and weekly thereafter (ie, every 7 days): ISL 20 mg and LEN 300 mg

    Drug: ISL · Drug: LEN

  • Experimental
    Cohort 1 (B/F/TAF to ISL+LEN)

    Participants will receive bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) 50/200/25 mg once daily for at least 48 weeks After 48 weeks, participants will switch from B/F/TAF to ISL+LEN * ISL 40 and LEN 600 mg on Day 1 and Day 2 * ISL 20 mg and LEN 300 mg weekly Participants who do not switch from B/F/TAF to ISL+LEN at Week 48 will be discontinued from the study.

    Drug: ISL · Drug: LEN · Drug: B/F/TAF

  • Experimental
    Cohort 2 (ISL+LEN)

    Participants will receive the following for at least 48 weeks * Day 1: LEN oral 600 mg (2 x 300 mg) and ISL 2 mg (2 x 1 mg) * Day 2: LEN only oral 600 mg (2 x 300 mg) * Day 8 and weekly thereafter (ie, every 7 days): LEN oral 300 mg (1 x 300 mg) and ISL 2 mg

    Drug: ISL · Drug: LEN

  • Experimental
    Cohort 2 (B/F/TAF to ISL+LEN)

    Participants will receive B/F/TAF 50/200/25 mg once daily for at least 48 weeks.

    Drug: ISL · Drug: LEN · Drug: B/F/TAF

  • Experimental
    Extension Phase Cohort 2 of ISL/LEN Fixed Dose Combination (FDC)

    After 48 Weeks of randomized treatment, all participants will be given an option to participate in an Extension Phase to receive ISL+LEN or ISL/LEN FDC tablet (when available) until ISL/LEN becomes available or until the sponsor elects to discontinue the study, whichever occurs first. Participants receiving ISL+LEN during the randomized phase will continue to take ISL + LEN weekly. Participants receiving B/F/TAF during the randomized phase will switch to ISL+LEN: * Day 1: LEN oral 600 mg (2 x 300 mg) and ISL 2 mg (2 x 1 mg) * Day 2: LEN only oral 600 mg (2 x 300 mg) * Day 8 and weekly thereafter (ie, every 7 days): LEN oral 300 mg (1 x 300 mg) and ISL 2 mg Participants who do not switch from B/F/TAF to ISL+LEN at Week 48 will be discontinued from the study. All participants in the extension phase will be transitioned to weekly ISL/LEN FDC (Dose A) tablet when it becomes available.

    Drug: ISL/LEN FDC

Interventions

  • DrugISL

    Capsules administered orally without regard to food

  • DrugLEN

    Tablets administered orally without regard to food

    Also known as: GS-6207

  • DrugB/F/TAF

    Drug pages: Bictegravir · Emtricitabine · Tenofovir alafenamide

    Tablets administered orally without regard to food

    Also known as: Biktarvy®

  • DrugISL/LEN FDC

    Tablets administered orally without regard to food

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 24 as Determined by the US Food and Drug Administration (FDA)-Defined Snapshot Algorithm

    The percentage of participants with HIV-1 RNA ≥ 50 copies/mL at Week 24 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with the applicable study drug discontinuation status. Week 24 window was between Day 148 and 189 (inclusive). Percentages were rounded off.

    Time frame: Week 24

Secondary outcomes

  1. Percentage of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 12 as Determined by the US FDA-defined Snapshot Algorithm

    The percentage of participants with HIV-1 RNA ≥ 50 copies/mL at Week 12 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with the applicable study drug discontinuation status. Week 12 window was between Day 71 and 105 (inclusive). Percentages were rounded off.

    Time frame: Week 12

  2. Percentage of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 48 as Determined by the US FDA-defined Snapshot Algorithm

    The percentage of participants with HIV-1 RNA ≥ 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with the applicable study drug discontinuation status. Week 48 window was between Day 316 and 378 (inclusive). Percentages were rounded off.

    Time frame: Week 48

  3. Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 12 as Determined by the US FDA-defined Snapshot Algorithm

    The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 12 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with the applicable study drug discontinuation status. Week 12 window was between Day 71 and 105 (inclusive). Percentages were rounded off.

    Time frame: Week 12

  4. Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 24 as Determined by the US FDA-defined Snapshot Algorithm

    The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 24 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with the applicable study drug discontinuation status. Week 24 window was between Day 148 and 189 (inclusive). Percentages were rounded off.

    Time frame: Week 24

  5. Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 as Determined by the US FDA-defined Snapshot Algorithm

    The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with the applicable study drug discontinuation status. Week 48 window was between Day 316 and 378 (inclusive). Percentages were rounded off.

    Time frame: Week 48

  6. Change From Baseline in Clusters of Differentiation 4 (CD4)+ Cell Count at Week 12

    Time frame: Baseline and Week 12

  7. Change From Baseline in CD4+ Cell Count at Week 24

    Time frame: Baseline and Week 24

  8. Change From Baseline in CD4+ Cell Count at Week 48

    Time frame: Baseline and Week 48

  9. Percentage of Participants Experiencing Treatment-Emergent Adverse Events Leading to Study Drug Discontinuation

    TEAEs were defined as 1 or both of any AEs leading to premature discontinuation of study drug, or any AEs with an onset date on or after the study drug start date and no later than the last exposure date after permanent discontinuation of the study drug. Percentages were rounded off.

    Time frame: Up to 5 years

  10. Cohort 1: Plasma Concentrations for ISL

    Time frame: Anytime postdose at Week 4

  11. Cohort 2: Pharmacokinetic (PK) Parameter: Cmax of Islatravir (ISL)

    Cmax was defined as the maximum observed concentration of drug.

    Time frame: Anytime post dose on Day 1 and at either Week 12 or Week 18

  12. Cohort 2: PK Parameter: Tmax of ISL

    Tmax was defined as the time (observed time point) of Cmax.

    Time frame: Anytime post dose on Day 1 and at either Week 12 or Week 18

  13. Cohort 2: PK Parameter: Ctau of ISL

    Ctau was defined as the observed drug concentration at the end of the dosing interval.

    Time frame: Anytime post dose at either Week 12 or Week 18

  14. Cohort 2: PK Parameter: AUCtau of ISL

    AUCtau was defined as concentration of drug over time (the area under the concentration verses time curve over the dosing interval).

    Time frame: Anytime post dose at either Week 12 or Week 18

  15. Plasma Concentrations for LEN

    Time frame: Anytime postdose at Week 4

  16. Cohort 2: Pharmacokinetic (PK) Parameter: Cmax of LEN

    Cmax was defined as the maximum observed concentration of drug.

    Time frame: Anytime post dose on Day 1, Day 2 and at either Week 12 or 18

  17. Cohort 2: PK Parameter: Tmax of LEN

    Tmax is defined as the time (observed time point) of Cmax.

    Time frame: Anytime post dose on Day 1, Day 2 and at either Week 12 or Week 18

  18. Cohort 2: PK Parameter: Ctau of LEN

    Ctau was defined as the observed drug concentration at the end of the dosing interval.

    Time frame: Anytime post dose at either Week 12 or Week 18

  19. Cohort 2: PK Parameter: AUCtau of LEN

    AUCtau was defined as concentration of drug over time (the area under the concentration verses time curve over the dosing interval).

    Time frame: Anytime post dose at either Week 12 or Week 18

07

Results

Posted Jan 14, 2025

Participant flow

Participants were enrolled at study sites in the United States. This is the primary results analysis including data up to Week 48 for the outcome measures. As Cohort 1 never reached Week 48, so, the data for some outcome measures for applicable timepoints up to Week 48 were reported for Cohort 2 only.

Participant flow — Overall Study
MilestoneCohort 1- Group 1 (ISL+LEN)Cohort 1- Group 2 (B/F/TAF to ISL+LEN)Cohort 2- Group 1 (ISL+LEN)Cohort2- Group 2 (B/F/TAF to ISL+LEN)
Started24125353
Completed0024
Not completed24125149
Withdrew: Still on study004744
Withdrew: Cohort terminated by sponsor211200
Withdrew: Withdrew consent1012
Withdrew: Lost to follow-up1002
Withdrew: Adverse event0020
Withdrew: Randomized but never treated0011
Withdrew: Protocol violation1000

Outcome measures

PrimaryPercentage of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 24 as Determined by the US Food and Drug Administration (FDA)-Defined Snapshot Algorithm

The percentage of participants with HIV-1 RNA ≥ 50 copies/mL at Week 24 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with the applicable study drug discontinuation status. Week 24 window was between Day 148 and 189 (inclusive). Percentages were rounded off.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 24 as Determined by the US Food and Drug Administration (FDA)-Defined Snapshot Algorithm
percentage of participantsCohort 1- Group 1 (ISL+LEN)Cohort 1- Group 2 (B/F/TAF to ISL+LEN)Cohort 2- Group 1 (ISL+LEN)Cohort2- Group 2 (B/F/TAF to ISL+LEN)
Percentage of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 24 as Determined by the US Food and Drug Administration (FDA)-Defined Snapshot Algorithm——1.90
SecondaryPercentage of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 12 as Determined by the US FDA-defined Snapshot Algorithm

The percentage of participants with HIV-1 RNA ≥ 50 copies/mL at Week 12 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with the applicable study drug discontinuation status. Week 12 window was between Day 71 and 105 (inclusive). Percentages were rounded off.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 12 as Determined by the US FDA-defined Snapshot Algorithm
percentage of participantsCohort 1- Group 1 (ISL+LEN)Cohort 1- Group 2 (B/F/TAF to ISL+LEN)Cohort 2- Group 1 (ISL+LEN)Cohort2- Group 2 (B/F/TAF to ISL+LEN)
Percentage of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 12 as Determined by the US FDA-defined Snapshot Algorithm——1.90
SecondaryPercentage of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 48 as Determined by the US FDA-defined Snapshot Algorithm

The percentage of participants with HIV-1 RNA ≥ 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with the applicable study drug discontinuation status. Week 48 window was between Day 316 and 378 (inclusive). Percentages were rounded off.

Time frame:
Week 48
Reported as:
Number · percentage of participants
Percentage of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 48 as Determined by the US FDA-defined Snapshot Algorithm
percentage of participantsCohort 1- Group 1 (ISL+LEN)Cohort 1- Group 2 (B/F/TAF to ISL+LEN)Cohort 2- Group 1 (ISL+LEN)Cohort2- Group 2 (B/F/TAF to ISL+LEN)
Percentage of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 48 as Determined by the US FDA-defined Snapshot Algorithm——00
SecondaryPercentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 12 as Determined by the US FDA-defined Snapshot Algorithm

The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 12 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with the applicable study drug discontinuation status. Week 12 window was between Day 71 and 105 (inclusive). Percentages were rounded off.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 12 as Determined by the US FDA-defined Snapshot Algorithm
percentage of participantsCohort 1- Group 1 (ISL+LEN)Cohort 1- Group 2 (B/F/TAF to ISL+LEN)Cohort 2- Group 1 (ISL+LEN)Cohort2- Group 2 (B/F/TAF to ISL+LEN)
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 12 as Determined by the US FDA-defined Snapshot Algorithm——98.1 (89.7 to 100)96.2 (86.8 to 99.5)
Statistical analysis
  • Cohort 2- Group 1 (ISL+LEN) vs Cohort2- Group 2 (B/F/TAF to ISL+LEN) · Difference in percentage: 1.9 · 95% CI -6.8 to 11.6The difference in percentages between treatment groups and their 95% CI were calculated based on unconditional exact method using 2 inverted 1-sided tests.
SecondaryPercentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 24 as Determined by the US FDA-defined Snapshot Algorithm

The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 24 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with the applicable study drug discontinuation status. Week 24 window was between Day 148 and 189 (inclusive). Percentages were rounded off.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 24 as Determined by the US FDA-defined Snapshot Algorithm
percentage of participantsCohort 1- Group 1 (ISL+LEN)Cohort 1- Group 2 (B/F/TAF to ISL+LEN)Cohort 2- Group 1 (ISL+LEN)Cohort2- Group 2 (B/F/TAF to ISL+LEN)
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 24 as Determined by the US FDA-defined Snapshot Algorithm——94.2 (84.1 to 98.8)96.2 (86.8 to 99.5)
Statistical analysis
  • Cohort 2- Group 1 (ISL+LEN) vs Cohort2- Group 2 (B/F/TAF to ISL+LEN) · Difference in percentage: -1.9 · 95% CI -12.4 to 8.6The difference in percentages between treatment groups and their 95% CI were calculated based on unconditional exact method using 2 inverted 1-sided tests.
SecondaryPercentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 as Determined by the US FDA-defined Snapshot Algorithm

The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with the applicable study drug discontinuation status. Week 48 window was between Day 316 and 378 (inclusive). Percentages were rounded off.

Time frame:
Week 48
Reported as:
Number · percentage of participants
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 as Determined by the US FDA-defined Snapshot Algorithm
percentage of participantsCohort 1- Group 1 (ISL+LEN)Cohort 1- Group 2 (B/F/TAF to ISL+LEN)Cohort 2- Group 1 (ISL+LEN)Cohort2- Group 2 (B/F/TAF to ISL+LEN)
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 as Determined by the US FDA-defined Snapshot Algorithm——96.2 (86.8 to 99.5)94.2 (84.1 to 98.8)
Statistical analysis
  • Cohort 2- Group 1 (ISL+LEN) vs Cohort2- Group 2 (B/F/TAF to ISL+LEN) · Difference in percentage: 1.9 · 95% CI -8.6 to 12.4The difference in percentages between treatment groups and their 95% CI were calculated based on unconditional exact method using 2 inverted 1-sided tests.
SecondaryChange From Baseline in Clusters of Differentiation 4 (CD4)+ Cell Count at Week 12
Time frame:
Baseline and Week 12
Reported as:
Mean · cells/µL
Change From Baseline in Clusters of Differentiation 4 (CD4)+ Cell Count at Week 12
cells/µLCohort 1- Group 1 (ISL+LEN)Cohort 1- Group 2 (B/F/TAF to ISL+LEN)Cohort 2- Group 1 (ISL+LEN)Cohort2- Group 2 (B/F/TAF to ISL+LEN)
Baseline721 ± 265.0659 ± 304.8755 ± 223.6818 ± 271.3
Change at Week 12-50 ± 183.018 ± 142.3-23 ± 185.6-49 ± 180.0
Statistical analysis
  • Cohort 1- Group 1 (ISL+LEN) vs Cohort 1- Group 2 (B/F/TAF to ISL+LEN) · ANOVA · p = 0.3859 · Difference in least squares means: -68 · 95% CI -226 to 91P-value, difference in least squares means (Diff in LSM), and its 95% confidence interval (CI) were from ANOVA model with treatment group as a fixed effect in the model.
  • Cohort 2- Group 1 (ISL+LEN) vs Cohort2- Group 2 (B/F/TAF to ISL+LEN) · ANCOVA · p = 0.7085 · Difference in least squares means: 13 · 95% CI -56 to 82P-value, difference in least squares means (Diff in LSM), and its 95% CI were from ANCOVA model with baseline value as a covariate and treatment as a fixed effect in the model.
SecondaryChange From Baseline in CD4+ Cell Count at Week 24
Time frame:
Baseline and Week 24
Reported as:
Mean · cells/µL
Change From Baseline in CD4+ Cell Count at Week 24
cells/µLCohort 1- Group 1 (ISL+LEN)Cohort 1- Group 2 (B/F/TAF to ISL+LEN)Cohort 2- Group 1 (ISL+LEN)Cohort2- Group 2 (B/F/TAF to ISL+LEN)
Change From Baseline in CD4+ Cell Count at Week 24——-4 ± 182.1-57 ± 204.2
Statistical analysis
  • Cohort 2- Group 1 (ISL+LEN) vs Cohort2- Group 2 (B/F/TAF to ISL+LEN) · ANCOVA · p = 0.3477 · Difference in least squares means: 33 · 95% CI -37 to 103P-value, difference in least squares means (Diff in LSM), and its 95% CI were from ANCOVA model with baseline value as a covariate and treatment as a fixed effect in the model.
SecondaryChange From Baseline in CD4+ Cell Count at Week 48
Time frame:
Baseline and Week 48
Reported as:
Mean · cells/µL
Change From Baseline in CD4+ Cell Count at Week 48
cells/µLCohort 1- Group 1 (ISL+LEN)Cohort 1- Group 2 (B/F/TAF to ISL+LEN)Cohort 2- Group 1 (ISL+LEN)Cohort2- Group 2 (B/F/TAF to ISL+LEN)
Change From Baseline in CD4+ Cell Count at Week 48——-12 ± 214.7-29 ± 186.1
Statistical analysis
  • Cohort 2- Group 1 (ISL+LEN) vs Cohort2- Group 2 (B/F/TAF to ISL+LEN) · ANCOVA · p = 0.8849 · Difference in least squares means: -5 · 95% CI -76 to 66P-value, difference in least squares means (Diff in LSM), and its 95% CI were from ANCOVA model with baseline value as a covariate and treatment as a fixed effect in the model.
SecondaryPercentage of Participants Experiencing Treatment-Emergent Adverse Events Leading to Study Drug Discontinuation

TEAEs were defined as 1 or both of any AEs leading to premature discontinuation of study drug, or any AEs with an onset date on or after the study drug start date and no later than the last exposure date after permanent discontinuation of the study drug. Percentages were rounded off.

Time frame:
Up to 5 years

Results for this outcome have not been posted.

SecondaryCohort 1: Plasma Concentrations for ISL
Time frame:
Anytime postdose at Week 4
Reported as:
Mean · ng/mL
Cohort 1: Plasma Concentrations for ISL
ng/mLCohort 1- Group 1 (ISL+LEN)
Cohort 1: Plasma Concentrations for ISL42.1 ± 49.6
SecondaryCohort 2: Pharmacokinetic (PK) Parameter: Cmax of Islatravir (ISL)

Cmax was defined as the maximum observed concentration of drug.

Time frame:
Anytime post dose on Day 1 and at either Week 12 or Week 18
Reported as:
Mean · ng/mL
Cohort 2: Pharmacokinetic (PK) Parameter: Cmax of Islatravir (ISL)
ng/mLCohort 2- Group 1 (ISL+LEN)
Day 119.6 ± 6.55
Week 12 or Week 1818.7 ± 7.6
SecondaryCohort 2: PK Parameter: Tmax of ISL

Tmax was defined as the time (observed time point) of Cmax.

Time frame:
Anytime post dose on Day 1 and at either Week 12 or Week 18
Reported as:
Mean · hours
Cohort 2: PK Parameter: Tmax of ISL
hoursCohort 2- Group 1 (ISL+LEN)
Day 11.12 ± 1.03
Week 12 or Week 180.793 ± 0.423
SecondaryCohort 2: PK Parameter: Ctau of ISL

Ctau was defined as the observed drug concentration at the end of the dosing interval.

Time frame:
Anytime post dose at either Week 12 or Week 18
Reported as:
Mean · ng/mL
Cohort 2: PK Parameter: Ctau of ISL
ng/mLCohort 2- Group 1 (ISL+LEN)
Cohort 2: PK Parameter: Ctau of ISL0.169 ± 0.0940
SecondaryCohort 2: PK Parameter: AUCtau of ISL

AUCtau was defined as concentration of drug over time (the area under the concentration verses time curve over the dosing interval).

Time frame:
Anytime post dose at either Week 12 or Week 18
Reported as:
Mean · h*ng/mL
Cohort 2: PK Parameter: AUCtau of ISL
h*ng/mLCohort 2- Group 1 (ISL+LEN)
Cohort 2: PK Parameter: AUCtau of ISL132 ± 98.1
SecondaryPlasma Concentrations for LEN
Time frame:
Anytime postdose at Week 4
Reported as:
Mean · ng/mL
Plasma Concentrations for LEN
ng/mLCohort 1- Group 1 (ISL+LEN)
Plasma Concentrations for LEN62.0 ± 43.9
SecondaryCohort 2: Pharmacokinetic (PK) Parameter: Cmax of LEN

Cmax was defined as the maximum observed concentration of drug.

Time frame:
Anytime post dose on Day 1, Day 2 and at either Week 12 or 18
Reported as:
Mean · ng/mL
Cohort 2: Pharmacokinetic (PK) Parameter: Cmax of LEN
ng/mLCohort 2- Group 1 (ISL+LEN)
Day 146.4 ± 29.0
Day 2183 ± 189
Week 12 or Week 1897.4 ± 73.2
SecondaryCohort 2: PK Parameter: Tmax of LEN

Tmax is defined as the time (observed time point) of Cmax.

Time frame:
Anytime post dose on Day 1, Day 2 and at either Week 12 or Week 18
Reported as:
Mean · hours
Cohort 2: PK Parameter: Tmax of LEN
hoursCohort 2- Group 1 (ISL+LEN)
Day 111.4 ± 8.96
Day 26.61 ± 1.47
Week 12 or Week 185.43 ± 1.63
SecondaryCohort 2: PK Parameter: Ctau of LEN

Ctau was defined as the observed drug concentration at the end of the dosing interval.

Time frame:
Anytime post dose at either Week 12 or Week 18
Reported as:
Mean · ng/mL
Cohort 2: PK Parameter: Ctau of LEN
ng/mLCohort 2- Group 1 (ISL+LEN)
Cohort 2: PK Parameter: Ctau of LEN36.6 ± 22.5
SecondaryCohort 2: PK Parameter: AUCtau of LEN

AUCtau was defined as concentration of drug over time (the area under the concentration verses time curve over the dosing interval).

Time frame:
Anytime post dose at either Week 12 or Week 18
Reported as:
Mean · h*ng/mL
Cohort 2: PK Parameter: AUCtau of LEN
h*ng/mLCohort 2- Group 1 (ISL+LEN)
Cohort 2: PK Parameter: AUCtau of LEN10000 ± 7440

Adverse events

Collected over All-Cause Mortality: Cohort 1: Up to Week 12; Cohort 2: Up to Week 74.6. Adverse Events: Cohort 1: Up to Week 12; Cohort 2: Up to Week 48. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 1- Group 1 (ISL+LEN)0/24 (0%)0/24 (0%)11/24 (45.8%)
Cohort 1- Group 2 (B/F/TAF to ISL+LEN)0/12 (0%)0/12 (0%)7/12 (58.3%)
Cohort 2- Group 1 (ISL+LEN)0/53 (0%)3/52 (5.8%)27/52 (51.9%)
Cohort2- Group 2 (B/F/TAF to ISL+LEN)0/53 (0%)0/52 (0%)29/52 (55.8%)
Most frequent serious events
Most frequent serious events
EventCohort 1- Group 1 (ISL+LEN)Cohort 1- Group 2 (B/F/TAF to ISL+LEN)Cohort 2- Group 1 (ISL+LEN)Cohort2- Group 2 (B/F/TAF to ISL+LEN)
Large intestine perforationGastrointestinal disorders0/240/121/520/52
PneumoniaInfections and infestations0/240/121/520/52
Anaesthetic complication neurologicalInjury, poisoning and procedural complications0/240/121/520/52
Renal colicRenal and urinary disorders0/240/121/520/52
Most frequent other events
Showing 10 of 21
Most frequent other events
EventCohort 1- Group 1 (ISL+LEN)Cohort 1- Group 2 (B/F/TAF to ISL+LEN)Cohort 2- Group 1 (ISL+LEN)Cohort2- Group 2 (B/F/TAF to ISL+LEN)
Covid-19Infections and infestations7/242/126/526/52
Pain in extremityMusculoskeletal and connective tissue disorders0/242/123/523/52
Upper respiratory tract infectionInfections and infestations1/240/127/527/52
DiarrhoeaGastrointestinal disorders0/240/126/523/52
ArthralgiaMusculoskeletal and connective tissue disorders1/240/123/525/52
CoughRespiratory, thoracic and mediastinal disorders0/240/120/525/52
NauseaGastrointestinal disorders2/240/123/521/52
FolliculitisInfections and infestations1/241/122/520/52
SinusitisInfections and infestations1/241/121/521/52
HypercholesterolaemiaMetabolism and nutrition disorders0/241/120/520/52

Baseline characteristics

Safety analysis set included all participants who received at least 1 dose of study drugs.

Age, Categorical
Age, Categorical(Participants)Cohort 1- Group 1 (ISL+LEN)Cohort 1- Group 2 (B/F/TAF to ISL+LEN)Cohort 2- Group 1 (ISL+LEN)Cohort2- Group 2 (B/F/TAF to ISL+LEN)Total
<=18 years00000
Between 18 and 65 years22125046130
>=65 years202610
Age, Continuous
Age, Continuous(years)Cohort 1- Group 1 (ISL+LEN)Cohort 1- Group 2 (B/F/TAF to ISL+LEN)Cohort 2- Group 1 (ISL+LEN)Cohort2- Group 2 (B/F/TAF to ISL+LEN)Total
Mean42 ± 11.940 ± 11.243 ± 12.145 ± 13.343 ± 12.4
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1- Group 1 (ISL+LEN)Cohort 1- Group 2 (B/F/TAF to ISL+LEN)Cohort 2- Group 1 (ISL+LEN)Cohort2- Group 2 (B/F/TAF to ISL+LEN)Total
Female2110922
Male22114243118
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cohort 1- Group 1 (ISL+LEN)Cohort 1- Group 2 (B/F/TAF to ISL+LEN)Cohort 2- Group 1 (ISL+LEN)Cohort2- Group 2 (B/F/TAF to ISL+LEN)Total
Hispanic or Latino74131741
Not Hispanic or Latino178393599
Unknown or Not Reported00000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Cohort 1- Group 1 (ISL+LEN)Cohort 1- Group 2 (B/F/TAF to ISL+LEN)Cohort 2- Group 1 (ISL+LEN)Cohort2- Group 2 (B/F/TAF to ISL+LEN)Total
White106252768
Black or African American135211655
Other or More Than One Race10359
Asian01214
American Indian or Alaska Native00123
Native Hawaiian or Other Pacific Islander00011
Region of Enrollment
Region of Enrollment(Participants)Cohort 1- Group 1 (ISL+LEN)Cohort 1- Group 2 (B/F/TAF to ISL+LEN)Cohort 2- Group 1 (ISL+LEN)Cohort2- Group 2 (B/F/TAF to ISL+LEN)Total
United States24125252140
08

Study locations

44 sites
09

References and documents

Publications

  • Colson AE, Crofoot GE, Ruane PJ, Ramgopal MN, Dretler AW, Nahass RG, Sinclair GI, Berhe M, Roberts A, Applin S, Brinson C, Jayaweera D, Workowski KA, Shihadeh F, Liu SY, Klopfer S, Llamoso C, Madera S, Dvory-Sobol H, Rhee MS, Rhee EG, Baeten JM, Eron JJ. Once-Weekly Oral Islatravir Plus Lenacapavir Versus Daily Oral Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Persons With HIV-1 : A Phase 2 Randomized Study. Ann Intern Med. 2026 Feb;179(2):168-176. doi: 10.7326/ANNALS-25-01939. Epub 2025 Dec 23. PubMed 41429026 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2021 to primary completion in Dec 2023, 26 months.

Results were first posted in Jan 2025, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 13, 2021
First posted
Sep 22, 2021
StartActual
Oct 5, 2021
Primary completionActual
Dec 19, 2023
CompletionEst.
Mar 2028
Results first posted
Jan 14, 2025
Last update
Feb 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05052996
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Sep 22, 2021
Start date
Oct 5, 2021
Primary completion
Dec 19, 2023
Completion
Mar 2028 (estimated)
Results posted
Jan 14, 2025
Last update
Feb 4, 2026

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Islatravir · Lenacapavir

Start the discussion